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aBstraCt
The application of drops containing ocular medicines to the conjunctival sac is the most common method of drug 
delivery to the anterior segment of the eye. Although this route of application seemingly displays numerous ad-
vantages, obtaining effective drug concentration at its site of action is challenging. The bioavailability of a topically 
applied drug depends on various factors related to the eye, to the drug and formulation, to the drop, and to the 
patient. The present article discusses their relative significance. From a drop applied to an eye, at most 5% of a drug 
dose enters the ocular structures. Of utmost importance for effective ocular drug delivery are patient compliance 
and the physicochemical properties of the drug. For a given concentration of an active substance, drop size may 
determine drug adverse effects but does not influence its efficacy. 
Key words: ocular drops, drug bioavailability, side effects, patient compliance
Ophthalmol J 2016; Vol. 1, No. 1, 29–35
introduCtion
Application of drops containing a medicine top-
ically to the conjunctival sac is the most common 
method of ocular drug delivery. Such applied med-
icines are widely used for the treatment of diseases 
of the anterior segment of the eye: cornea, conjunc-
tiva, episclera, and sclera, as well as deeper intraoc-
ular structures: iris and ciliary body. Antibiotics, 
steroids, non-steroid anti-inflammatory drugs, and 
IOP-decreasing anti-glaucoma drugs are given in 
such a way. The advantages of eye drops are fre-
quently presented to include the following: relative 
ease and non-invasiveness of self-administration, 
direct targeting of the desired destination, bypass-
ing the first-pass liver metabolism, and minimising 
systemic side effects. In reality, for an ocular drug 
topically applied, such as eye drops, reaching an ef-
fective concentration at the site of action and main-
taining it for a desired time is challenging, mainly 
because of the short ocular contact time of the active 
principle due to it being washed away through the 
lacrimal system, diluting with tears, and poor pen-
etration to the eye.
To reach a destination site, a drug applied in eye 
drops must cross anatomical barriers and bypass 
protective mechanisms of the eye. When we con-
sider so-called innovator drugs that receive market 
authorization on the basis of a full registration dos-
sier that includes clinical studies proving safety and 
therapeutic efficacy, particulars of drug substance 
penetration into, and retention at, the site of action 
are of no practical importance. The situation is dif-
ferent when we consider generics. 
The European Medicines Agency [1] defines ge-
neric medicine as a medicine that is developed to 
be the same as a medicine that has already been au-
thorised (the ‘reference medicine’). Furthermore, it is 
stated that a generic medicine contains the same quan-
tity of active substance(s) as the reference medicine. 
However: The inactive ingredients, or ‘excipients’, may 
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differ between the generic medicine and its reference. 
[This is possible because] …the active substance of 
a medicine is what gives it its therapeutic effect. 
Any pharmacological treatment requires de-
livery of an active substance to, and establishing 
its effective concentration at, a destination site for 
a required period of time. When a drug is given 
parenterally or orally, these conditions are in most 
cases approximated by the area under the curve 
(AUC), a parameter obtained by integrating drug 
concentrations measured in blood plasma at certain 
discrete time points. A generic variant of a reference 
drug is deemed acceptable if its average AUC value 
lies within an 80–125% interval from the average 
AUC of the reference drug and the difference is not 
statistically significant. However, in the case of eye 
drops the blood plasma AUC is irrelevant. 
Multiple generic variants of reference formula-
tions of eye drops are market approved in the Euro-
pean Union and the USA, but their comparability 
and interchangeability is sometimes debated, see 
e.g. [2]. Doubts are fuelled by reports on seemingly 
profound differences between various brands of eye 
drops. Apparently excipients and containers from 
which drops are delivered may markedly influence 
drug bioavailability; excipients can also alter toler-
ability to eye drops. For chronically applied drugs, 
such as those used to treat glaucoma, even small dif-
ferences between drug brands may be of significance. 
Mammo et al. [3] compared volumes of dif-
ferent brands of reference and generic topical eye 
drops available in the USA and Canada and found, 
inter alia, that one generic brand of timolol maleate 
(gel-based formulation) delivered approximately 
40% less drop volume than its reference formula-
tion, whereas the other generic brand of timolol 
maleate (ophthalmic solution formulation) deliv-
ered approximately 20% less drop volume than its 
reference formulation. Are these generics equiva-
lent to their respective references? Leitritz et al. [4] 
compared the reference and 23 different generic 
brands of a leading anti-glaucoma drug latanoprost 
available in Germany and also found noticeable dif-
ferences in the contents of both the active substance 
and the main excipient (benzalkonium chloride) in 
the drop’s mass and the pH of the solution, and in 
bottle forms. The authors suggested that before pre-
scribing generic eye drops in ophthalmology various 
factors have to be considered that might influence 
the therapeutic effect. Unfortunately, they did not 
provide any guidance on which factors are more, 
and which are less important.
The aim of the present article is to discuss factors 
that determine the bioavailability of active prin-
ciples from topically applied eye drops. They are 
conventionally classified into four groups: eye-relat-
ed, drug and formulation-related, drop-related, and 
patient-related. Although these factors influence 
each other, their relative importance, by which we 
mean their contribution to the overall performance 
of a drug, differ.
eye-related faCtors
The human eye is an extremely important and 
sensitive sensory organ; at the same time, it is a part 
of the body surface in continuous contact with the 
outer environment, tightly protected from foreign 
bodies and substances with several anatomical bar-
riers and precorneal factors. These protective mech-
anisms do not support bioavailability of drugs from 
eye drops. 
Anatomical barriers for a topical route of drug 
administration consist of cornea, conjunctiva, and 
sclera. Each of these has a different structure, reflect-
ed by different permeability to drug substances [5]. 
The cornea and conjunctiva make the ocular sur-
face. They are both covered with epithelium; addi-
tionally, mucous covers most of the outer surface 
of the eyeball [6]. The total surface area for the 
adult conjunctival sac of one eye (including the cor-
nea) averages 16 cm2 [7], and the corneal surface is 
17-times smaller than the conjunctival surface [8]. 
The cornea is avascular and consists of three lay-
ers: the epithelium, stroma, and endothelium. The 
corneal epithelium contains 90% of the total count 
of corneal cells, but it only represents ca. 10% of 
its thickness. It consists of six layers of non-kera-
tinised stratified squamous epithelium, permeable 
to lipophilic agents but significantly resistant to 
hydrophilic agents. Intercellular permeability is ad-
ditionally reduced by desmosomes and tight junc-
tional complexes (zonulae occludens). Conversely, 
the corneal stroma, which represents 90% of the 
corneal thickness, is built up mostly of collagen 
with a small number of cells. The highly hydrated 
structure of the stroma is permeable to hydrophilic 
agents but constitutes a barrier to lipophilic mol-
ecules. The innermost layer of the cornea consists 
of a single layer of hexagonally-shaped endothelial 
cells. Junctions between these cells are leaky, en-
abling passage of molecules; therefore, the inner 
corneal epithelium is not considered a barrier for 
topically administered drugs. 
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tear volume after application of the eye drop re-
quires about two to three minutes, and most of the 
topically administered solution is drained from the 
conjunctival sac during the first 15–30 seconds. The 
larger the volume instilled, the more rapidly it is 
drained through the nasolacrimal duct system [16]. 
The lacrimal system removes the agents 100-times 
faster than the cornea and conjunctiva are able to 
absorb them [17].
drug and forMulation-related 
faCtors 
Drug activity, i.e. pharmacodynamics, is me-
diated by a pharmacophore, i.e. a group of at-
oms necessary to ensure supramolecular interac-
tions with a specific target and trigger or block its 
bio logical response. Reaching the intended site by 
a drug, i.e. pharmacokinetics, is determined by its 
physicochemical properties, such as molecular size, 
lipophilicity/hydrophilicity, acidity, and charge. 
These properties can be manipulated during drug 
development to ensure optimal penetration through 
ocular barriers and effective exposure of a target. In 
some cases, the requirement of stability of a drug’s 
active substance during its shelf-life may limit the 
available options of a drug formulation. For exam-
Compared to the cornea, the conjunctiva is 
less permeable for lipophilic agents. Furthermore, 
tight junctions of conjunctival epithelium also re-
duce its permeability to hydrophilic molecules [9]. 
Nonetheless, dense vascularisation with blood and 
lymphatic vessels leads to absorption of drugs into 
circulation and reduces their bioavailability at the 
destination site. Both conjunctiva and the lacrimal 
drainage system are covered with stratified colum-
nar epithelium, whereas the nasal mucosa is covered 
with pseudostratified columnar epithelium with 
very highly vascularised lamina propria. Systemic 
absorption from nasal mucosa is much larger than 
from conjunctiva [10]. 
The other barrier on the route of a topically 
administered drug is the sclera, which is localised 
under the conjunctiva (known also as the white of 
the eye). Anatomically this tissue is continuous to 
the corneal stroma. It consists mostly of collagen 
fibres and proteoglycans. The permeability of drug 
molecules across the sclera is comparable to corneal 
stroma and is dependent on molecular radius and 
weight, hydrophilicity, and charge of the molecule. 
For hydrophilic agents it is 80-times faster than 
through all corneal layers. It is inversely proportion-
al to the molecular radius [11]. Positively charged 
molecules exhibit poor permeability, presumably 
due to their binding to the negatively charged pro-
teoglycan matrix [12]. 
In summary, respective anatomical eye barri-
ers are differently permeable to lipophilic and hy-
drophilic substances, to low- and high-molecular 
weight molecules, etc. Depending on physicochem-
ical properties, drugs applied topically follow dif-
ferent routes across anatomical barriers to enter the 
anterior chamber, as shown in Figure 1.
In addition to the aforementioned anatomical 
barriers, the eye is guarded by precorneal factors, 
which include blinking, induced lacrimation, tear 
film turnover, and drainage. The tear film is a first 
line hindrance against pathogens. Because of its 
pivotal role for vision, refraction, and lubrication, 
it is described as a sixth layer of the cornea. It is 
about 8 µm thick with a volume of 7 µL. The fluid 
from conjunctival sac is vacuumed to the lacrimal 
drainage system, lacrimal sac, and nasal cavity by 
a valve-like mechanism, described by Doane [14]. 
Tear production in normal conditions is about 
1 µL/min with a fluid turnover rate of 0.5 to 
2.2 µL/min [15]. Mechanical manipulation of eye-
lids needed to instil the drug will double or triple 
normal basal tear flow. Restoration of the normal 
figure 1. Pathways employed by drugs applied topically to 
cross anatomical barriers of the eye and enter the anterior cham-
ber. The main route is assumed to be via the cornea (1). Large 
and hydrophilic drugs prefer the conjunctival and scleral route (2) 
and then diffuse into the ciliary body (3). From the anterior cham-
ber the drugs are removed either by aqueous humour outflow (4) 
or by venous blood flow after diffusing across the iris surface (5). 
After systemic administration drugs must pass across the retinal 
pigment epithelium or the retinal capillary endothelium to reach 
the retina and vitreous humour (6). Alternatively, drugs can be 
administered by intravitreal injection (7). Drugs are eliminated 
from the vitreous via the blood–retinal barrier (8) or via diffusion 
into the anterior chamber (9). Reproduced from [13]
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ple, pilocarpine and epinephrine are stable only in 
acidic solutions, which on the other hand produce 
irritation immediately upon instillation and greatly 
increase lacrimation and drug dilution [18]. 
For ocular medicines applied as eye drops, 
enhancement of corneal permeability is favoura-
bly achieved by synthesising lipophilic ester pro-
drugs. When such prodrugs are topically applied, 
corneal epithelium and stroma act as a depot from 
which pharmacologically active acidic forms are 
liberated by corneal esterases. The prostaglandin 
analogues latanoprost and travoprost, currently the 
most frequently used anti-glaucoma drugs, are ex-
amples of such an approach [19]. Of note is that 
registration-wise, any new prodrug is a new drug 
that can be market-approved only on the basis of 
a full registration dossier.
The other way of enhancing corneal permeabili-
ty is to add to a drug formulation an excipient that 
acts as a permeation enhancer, i.e. a substance that 
increases the corneal penetration of a drug by mod-
ifying the integrity of corneal epithelium. The per-
meation enhancer most frequently encountered in 
eye drops is benzalkonium chloride (BAK), which 
also acts as an antimicrobial preservative and a solu-
biliser of poorly water-soluble drugs. While effective 
in increasing the corneal permeability in vitro and 
in vivo of many drugs, upon prolonged exposure 
BAK displays several negative effects on the eye. The 
compound accumulates in ocular tissues, where it 
may remain for a long period of time and induce 
cell death in a dose-dependent manner. After topi-
cal drop instillation BAK has been detected in the 
trabecular meshwork (TM), corneal endothelium, 
lens, and retina [20, 21]. The impact of prolonged 
BAK exposure has become a recognised issue in 
the management of glaucoma patients, particularly 
those with concurrent ocular surface disease. It has 
even been hypothesised recently that BAK may ac-
tually cause/worsen glaucoma, and this hypothesis is 
being tested experimentally in an animal model that 
closely reflects human physiology [22]. 
Preservatives, usually present in multi-use vials 
to prevent microbial contamination are blamed 
for conjunctival and palpebral side effects of eye 
drops [23], and sometimes also for damage of the 
ocular surface [24]. Preservative-free eye drops, 
packed in single-use containers or in bottles with 
aseptic filters, are better tolerated than drops con-
taining preservatives, see e.g. [25]. Interestingly, 
among currently used preservatives BAK shows the 
highest promoting effect on transcorneal drug pen-
etration [26], but its adverse effects are typically at-
tributed to antimicrobial properties but not to per-
meability-enhancing properties. Moreover, as shown 
in a clinical trial, a preservative-free formulation 
of latanoprost displays non-inferior IOP-reducing 
activ ity compared to the reference BAK-containing 
latanoprost formula [27]. The relative importance of 
permeability enhancers for ocular pharmacokinetics 
may be much smaller than expected. 
drop-related faCtors
Besides the anatomical and physiological proper-
ties of the human eye and physicochemical proper-
ties of a drug substance and excipients, the delivery 
of a drug depends on the amount of drug solution 
instilled to the eye surface. This, in turn, depends on 
the physicochemical properties of a drug and its ap-
plicator, and on a technique used by a patient to instil 
it to the eye. The quantity of active substance applied 
in a single droplet depends on its concentration and 
the volume of the droplet, which then depends on 
fluid viscosity, surface tension, temperature, cohesion 
forces, adhesion to the dropper tip aperture, dimen-
sions of the dropper tip, and application angle. 
On the other hand, in the conjunctival sac only 
the predetermined amount of drug can be held. The 
cornea and conjunctiva of the eyeball and eyelids 
form a cul-de-sac with a volume of 7–9 µL. By 
pulling the lower eyelid down this volume can be 
transiently increased to 30 µl, but reflective blinking 
reduces this effect and only 10 µl of instilled solution 
will remain in contact with the eye for longer than 
a few seconds [15]. Any excess instilled solution is 
lost by overflow and may be drained by the lacrimal 
system, becoming available for systemic absorption. 
This may result in side effects, local and/or system-
ic. For example, overflow of eye drops containing 
a prostaglandin analogue results in lengthening, 
thickening, and hyperpigmentation of eyelashes, and 
hyperpigmentation of the skin around the eye [28].
Commercially available eyedroppers typically 
deliver 25.1 µL to 56.4 µL, with an average drop 
volume of 39.0 µL [29]. They are multi-dose or sin-
gle-dose dispensers. In single-dose dispensers, which 
contain 0.1–1.0 mL of solution, the volume of the 
droplet depends on the dimensions of the orifice 
created in the tip. Difficulties in obtaining a smooth 
opening have been reported even when scissors were 
used. Multi-dose dispensers for eye drops usually 
consist of three parts: a bottle (volume between 
2.5 and 15 mL), a closure cap, and a tip (which 
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is the most important element in determining the 
drop volume). The tip has a channel with duct with 
calibrated narrower inner and wider outer aperture, 
which ensures accurate dispensing of the solution 
and prevents jetting while squeezing the bottle. The 
drop size is proportionally dependent on the outer 
aperture diameter [30]. Decreasing the outer aper-
ture size without changing the inner aperture diam-
eter results in a respective decrease in drop weight, 
but the relationship between inner diameter and 
drop size is not linear [31]. Additionally, the outer 
orifice has a hemispherical surface where the drop is 
formed and expelled, which prevents from acciden-
tal injury of the eye during administration. 
The most important physical factor influencing 
drop volume and its spherical shape is the surface 
tension of the fluid. According to Tate’s law the 
weight of a drop is directly proportional to the sur-
face tension of the solution. The volume of a droplet 
can be reduced by surface active substances (sur-
factants), which are added to eye drop formulations 
as preservatives and penetration enhancers. As men-
tioned previously, the most popular is benzalkonium 
chloride (BAK). Adding 0.01% of BAK to phosphate 
buffer solution reduces the droplet size from 43.7 µL 
to 31.5 µL [32]. When dispensing the smaller drops 
of the surface-active solutions, less force is needed to 
be exerted on the bottle and a lower dispensing time 
is noted. This could also be a practical advantage for 
elderly people experiencing physical difficulties with 
instilling their medication [33]. 
An important factor that determines the residence 
time of a drug on the eye surface is the viscosity of 
the instilled formulation. The viscosity of a fluid is 
a measure of its resistance to gradual deformation by 
shear stress or tensile stress; it is expressed in milipas-
cal-seconds (mPa·s). Ocular contact time, and hence 
the bioavailability, of a drug can be enhanced by 
increasing the viscosity of the ophthalmic formu-
lation. The addition of viscolysers, substances with 
high molecular weight, which barely cross biologi-
cal membranes, prolongs the retention time of the 
instilled fluid [34]. Human tears have a viscosity of 
about 1.5 mPa·s. Retention of solutions starts to in-
crease when the viscosity increases to 10 mPa·s [35], 
but modulation of viscosity in the range 5 to 
25 mPa·s barely influences the drop volume, which 
remains similar as in a non-viscous phosphate buffer 
solution. The ideal viscosity of ophthalmic solu-
tions is estimated to be 15–30 mPa·s. Solutions 
with higher viscosity cause discomfort and damage 
to ocu lar epithelia due to an increase in the shear 
stresses during blinking, and interference with eye-
lid movements, vision, and patient comfort.
patient-related faCtors
Patients’ behaviours have a profound multifacto-
rial influence on treatment performance. One factor 
is the angle of dispensing, the other is the number 
of drops reaching the ocular surface at a proper (or 
improper) time of day, and last but not least is long-
term adherence to treatment, which is particularly 
important in the case of IOP-lowering anti-glauco-
ma therapy, which requires chronic application of 
eye drops, usually for the patient’s lifetime. 
Patient handling of ocular medicines and instil-
lation technique influences drop size. It has been 
shown experimentally that the force used to squeeze 
the bottle dictates its volume. Squeezing the drop-
per bottle rapidly resulted in a higher weight of the 
drops dispensed and shorter time of their forma-
tion. Compression of the bottle with motor speed 
of 100 rpm results in a 5% increase of drop volume 
compared with 30 rpm [32]. This is a consequence 
of an increased tail at higher drop formation rates 
and extra impulse of liquid injected into the falling 
drop. At lower rates, the drop formation is slower 
and less or no extra liquid impulse is observed. By 
decreasing the speed of compressing the dropper 
bottle, the adsorption time is lengthened, resulting 
in a lower surface tension, which in turn influences 
the drop weight. It is recommended to instil eye 
drops with a 90° angle, keeping the bottle above 
the eye. However, in practice this angle is usually 
much smaller, it can be as low as 30°. Changing the 
dispensing angle from 90° to 45° causes a decrease 
of the mean drop weight of the phosphate buffer 
solution by about 10%. This can be explained by 
a reduction of the cross-sectional surface area of the 
outer aperture of the dropper tip [32].
When the strictest definition of noncompliance, 
i.e. not following the treatment as prescribed, was 
applied to a meta-analysis of data on treatment 
compliance, it transpired that up to 80% of glauco-
ma patients were non-compliant [36]. Some studies 
showed that less than one-third of the observed in-
stillations were performed successfully. An objective 
evaluation of eye drop instillation in patients with 
glaucoma showed that the mean number of instilled 
drops per administration was 1.8–2.6 [37, 38], only 
up to 40% of fluid steam was instilled, and only 
83% of patients were able to get the drop into the 
eye [39]. Interestingly, a recent four-year observa-
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tional study showed that adherence patterns ob-
served in the first year of treatment reflect adherence 
patterns over the subsequent three years [40].
The issue of topical glaucoma therapy is com-
plicated by the fact that the majority of primary 
open glaucoma patients are elderly. In a recent ob-
servational study [41] several barriers to optimal 
adherence were identified. The most frequently 
encountered were decreased self-efficacy, difficulty 
instilling drops, forgetfulness, and difficulties with 
the medication schedule.
ConClusions
Effective topical treatment of ocular diseases is 
a challenge. Even the best ocular drug will not be ef-
fective unless it is delivered to its site of action in suf-
ficient quantity. Interplay of many factors influences 
the delivery of a medicine to its site of action. Some 
of these factors can be precisely shaped, for example 
concentration, structure, and properties of an active 
substance (or its prodrug) and excipients. These as-
pects are the subject of scientific studies on technol-
ogies to improve the bioavailability of drugs. Human 
factors that can influence the volume of the drug are 
more difficult to control, although they may drasti-
cally impair the effectiveness of treatment. 
When a drug is instilled to the eye surface, the 
quantity that crosses the protective mechanisms of 
the eye is always much lower than that delivered in 
a drop formed by a dropper tip and applied into the 
conjunctival sac. It has been estimated that, even in 
optimal conditions, at most 5% of the instilled drug 
dose reaches the ocular target (Fig. 2). The volume 
exceeding the absorbed fraction does not implicate 
any therapeutic effect in the eye, thus we may con-
clude that even large differences in drop volume will 
have no influence on ocular drug performance. 
There is only one exception to this rule. It con-
cerns the possibility of non-ocular toxicity of an 
ocular drug. One such effect concerning overgrowth 
of eyelashes and hyperpigmentation of skin around 
the eye caused by the overspill of prostaglandin 
analogues has been mentioned previously. Even 
more important may be the possibility of periph-
erally-mediated effects of drugs applied topically to 
the eye, due to significant systemic absorption and 
bypassing liver first-pass metabolism. Bradycardia is 
a well-known effect of systemically absorbed frac-
tion of ophthalmic timolol [42]. In the first seven 
years after market approval of ophthalmic timolol 
in the USA, 450 serious adverse cardiopulmonary 
events were reported, of which 32 were fatal [43]. 
As already mentioned, ophthalmic drugs are 
available for multi- or single-dose administration in 
a wide variety of glass or plastic dropper bottles that 
deliver drops with a volume between 25 and 70 µL. 
Almost 40 years ago it was proposed that a decrease 
in drop size would not only reduce the amount of 
overflow and the rate of drug loss through drain-
age, but also reduce the incidence of systemic side 
effects [44]. Since then it has been accepted that, 
from a biopharmaceutical point of view, volumes 
of 5 to 15 µL should be instilled [45]. It is beyond 
figure 2. The fate of drugs instilled onto eye surface
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the expertise of the authors of the present article to 
provide an explanation as to why the recommended 
smaller size of ocular drops is not common in com-
mercially available eye drops. 
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